GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-2,709 Cr | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹-2,709 Cr |
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-2,709 Cr | Negative | |
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹68,489.9 Cr | -2.5% | 5.6% | 27.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,634.0 Cr | -2.9% | -2.3% | 21.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,576.0 Cr | -1.6% | 9.8% | 51.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -2.6% | -2.3% | 37.5% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | -2.2% | -6.1% | -12.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,322.1 Cr | -0.9% | -1.8% | -9.8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -2.5% |
5.6% |
27.5% |
| SENSEX | -1% |
-2.6% |
-4.1% |
You may also like the below Video Courses